PubMed indexes 7 records that name Fenofibrate and Fish Oil together, either in the title or in an interaction, co-administration, or pharmacokinetic context. The key findings come first, in the authors’ own words, followed by every study with its design and PubMed link.
A summary of published research, not medical advice. A pharmacist can check any combination against your full list of medicines and supplements.
Reviews and human studies first. Each quote is the authors’ own conclusion about their study, not a NutriStack assessment, and a single study is not a consensus.
“In a real-world setting, fenofibrate use was associated with a lower risk of MACE compared with low-dose omega-3 fatty acids when added to statins in people with metabolic syndrome.”
“Our results show that OM-3CA and fenofibrate differentially modulate the plasma mediator lipidome, with OM-3CA promoting the formation of lipid mediators with potential effects on chronic inflammation, while fenofibrate mainly reducing ceramides. These findings suggest that both treatments could ameliorate chronic inflammation with possible impact on disease outcomes, independent of triglyceride reduction.”
“The omega-3 group exhibited an upward trend in high-density lipoprotein-cholesterol (HDL-C) levels (p = .004), and intergroup differences were statistically significant (p = .038). Fenofibrate appeared to be a safe and effective candidate for TG lowering in pediatrics with hypertriglyceridemia, though further clinical research is recommended.”
The research
7 studies naming Fenofibrate and Fish Oil.
Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021 · PMID 34618982
Multicenter StudyRandomized Controlled Trial
“Our results show that OM-3CA and fenofibrate differentially modulate the plasma mediator lipidome, with OM-3CA promoting the formation of lipid mediators with potential effects on chronic inflammation, while fenofibrate mainly reducing ceramides. These findings suggest that both treatments could ameliorate chronic inflammation with possible impact on disease outcomes, independent of triglyceride reduction.”
Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners · 2026 · PMID 41636674
“The omega-3 group exhibited an upward trend in high-density lipoprotein-cholesterol (HDL-C) levels (p = .004), and intergroup differences were statistically significant (p = .038). Fenofibrate appeared to be a safe and effective candidate for TG lowering in pediatrics with hypertriglyceridemia, though further clinical research is recommended.”
European heart journal. Cardiovascular pharmacotherapy · 2024 · PMID 38017618
Human subjects
“In a real-world setting, fenofibrate use was associated with a lower risk of MACE compared with low-dose omega-3 fatty acids when added to statins in people with metabolic syndrome.”
Archives of medical sciences. Atherosclerotic diseases · 2024 · PMID 38434941
“Rosuvastatin and/or fenofibrate treatment increases Lp(a) levels in patients with mixed hyperlipidemia. Novel therapies should target Lp(a) level reduction to decrease the residual ASCVD risk in patients with mixed hyperlipidemia.”
The Medical letter on drugs and therapeutics · 2019 · PMID 30845107
Comparative StudyHuman subjects
Names Fenofibrate and Fish Oil together in an interaction, co-administration, or pharmacokinetic context.
Limitations
What this evidence cannot tell you.
Search-based evidence indexes have real limits, and it is worth being explicit about them:
Selection. These records were found by searching PubMed titles and abstracts for both substance names alongside interaction and pharmacokinetic terms. Relevant work that phrases things differently, or is not indexed in PubMed, will be missing.
No effect size. The quoted conclusions are the authors’ words about their own study. We have not extracted effect direction or magnitude, and a single study’s conclusion is not a consensus.
Population mismatch. Findings in healthy volunteers, animals, or a specific patient group may not transfer to you, your dose, or your formulation.
Absence is not safety. Few published studies means the combination is under-studied, which is not the same as established as safe.
How to read this page
A literature summary, not guidance.
A study listed here is not proof that Fenofibrate and Fish Oil interact. Two substances can be named together in a paper that never tested them in combination, and a source listed as background may cover only one of them.
Findings are quoted from each abstract as the authors wrote them. NutriStack has not re-analysed, pooled, or reconciled them, and they may disagree with each other.
Decisions about prescription medication and supplements belong with your prescriber or pharmacist, who can see your full regimen. Our timing guide and forms guide explain the general mechanisms.
Nearby evidence
Other pairs with published research.
Pages covering Fenofibrate or Fish Oil alongside a different substance.
NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Fenofibrate, Fish Oil, and several hundred other substances.
Log your routine, get reminders at the times you choose, and scan a label to add a product. The checker is a research and organisation tool, not a clinical decision aid.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
